Well, it took me long enough to comment on this excellent serial report from @StevenBrill on @HuffingtonPost about drug company tactics. J&J/Janssen held back data about serious problems their drug caused while continuing to tout their “putting patients first” credo. Hmmm, does that mean “first to harm?” Thanks to https://chaoticpharmacology.com/ and @pharmagossip for kicking me in gear.
Disclosure: I started the series, but didn’t finish – too incredulous at the hubris and twisted perspective of the company. I will now.
Unfortunately, they aren’t the only company exhibiting this pattern. It’s also not the only example of their dubious practices. NASDAQ also wrote this article about another J&J product: “Johnson & Johnson Settling Cases Tied to Device That Spread Uterine Cancer.”